Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Kizoo Technology Capital is a venture capital firm based in Karlsruhe, Germany, established in 2000. The firm is part of Michael Greve's Forever Healthy Group and is recognized as one of the leading investors in the longevity biotech sector. Kizoo focuses on rejuvenation biotechnology, aiming to transform aging research into viable therapies that can significantly extend healthy lifespans. The firm has committed approximately $600 million to its investment strategy, which emphasizes innovative technologies that address age-related diseases at the cellular and molecular levels.
Over the years, Kizoo has evolved from its initial investments in internet and SaaS sectors to a concentrated focus on longevity biotech. This shift reflects the firm’s commitment to addressing the challenges of aging through scientific advancements. Kizoo's portfolio currently includes 10 companies, showcasing its dedication to supporting groundbreaking research and development in rejuvenation technologies. The firm operates globally, collaborating with various stakeholders to ensure that innovative therapies reach the market effectively.
Kizoo Technology Capital primarily invests in the rejuvenation and longevity biotech sector, targeting technologies that aim to reverse age-related cellular changes. The firm’s investment strategy emphasizes novel drug compounds and therapies designed to prevent and treat aging-related conditions. Kizoo is particularly interested in groundbreaking technologies that address the aging process itself, believing that aging diseases can be prevented and reversed by tackling their common root causes.
The firm focuses on seed, Series A, Series B, and growth equity stages, providing substantial capital to support promising startups. While Kizoo has a history of involvement in the internet and SaaS sectors, its current investment strategy is predominantly centered on longevity biotech. The firm seeks to partner with founders who are developing innovative solutions in this field, leveraging its extensive expertise and network within the Forever Healthy Group to guide startups through the complexities of clinical development and commercialization.
Kizoo Technology Capital's portfolio includes several notable companies focused on rejuvenation and longevity biotech:
In addition to these companies, Kizoo has also invested in other firms such as Staffbase, Mambu, MOQO, and Babbel, although these are not the primary focus of their current investment strategy. The firm’s commitment to rejuvenation biotech positions it as a significant player in the global landscape of longevity investments.
Michael Greve — Founder and Managing Partner. Michael Greve is a German entrepreneur and longevity advocate with extensive experience in the biotech sector. He leads Kizoo Technology Capital as part of the Forever Healthy Group, focusing on transforming aging research into viable therapies. Greve's background includes a strong commitment to rejuvenation biotechnology and a vision for extending healthy lifespans through innovative solutions.
While additional team members are not specified in the source data, Kizoo's association with the Forever Healthy Group suggests a collaborative environment with access to a broader network of experts in longevity and rejuvenation biotech.
To pitch Kizoo Technology Capital, founders should visit their website at kizoo.com. It is recommended to include a comprehensive deck that outlines the technology, market potential, team qualifications, and the specific problem being addressed. Kizoo prefers detailed information on the scientific basis of the technology and its relevance to rejuvenation and longevity.
Response times may vary, but founders should expect a thorough review process given the firm's focus on specialized biotech investments. Warm introductions through mutual connections within the biotech community can enhance the chances of securing a meeting with Kizoo.
In recent months, Kizoo Technology Capital has continued to strengthen its position in the rejuvenation biotech sector. The firm has made several investments in startups focused on innovative technologies aimed at extending healthy lifespans. Notable portfolio additions include MoglingBio, which focuses on rejuvenating old stem cells, and Cellvie, a Harvard spin-off pioneering Therapeutic Mitochondria Transfer.
Kizoo's commitment to follow-on investments has also been highlighted, with substantial capital allocated to support promising companies as they advance their therapies from development to public availability. This ongoing activity underscores Kizoo's role as a significant player in the longevity biotech investment landscape.
What are Kizoo's investment criteria?
Kizoo Technology Capital invests in companies focused on rejuvenation and longevity biotech. They look for groundbreaking technologies that aim to reverse age-related cellular changes and address diseases associated with aging. The firm primarily targets seed, Series A, Series B, and growth equity stages.
How can startups apply or pitch to Kizoo?
Startups interested in pitching to Kizoo Technology Capital can do so through their website at kizoo.com. It is advisable to include a detailed overview of the technology, the team, and the potential impact on longevity and rejuvenation.
What makes Kizoo different from other venture capital firms?
Kizoo Technology Capital is distinct due to its exclusive focus on rejuvenation and longevity biotech. The firm is part of the Forever Healthy Group, which provides a unique network and resources for startups in this specialized field. Their substantial capital commitment of approximately $600 million also sets them apart as a major player in longevity investments.
What is Kizoo's geographic scope?
Kizoo operates globally, seeking innovative technologies that address aging and related diseases from startups around the world. Their investment strategy is not limited to specific regions, allowing them to tap into a diverse range of opportunities.
What kind of post-investment involvement does Kizoo have?
Kizoo Technology Capital provides significant support to its portfolio companies, leveraging its deep expertise in rejuvenation biotech and its extensive network within the Forever Healthy Group. The firm assists startups in navigating clinical development and commercialization processes, ensuring that innovative therapies reach the market effectively.
What is the typical check size for investments?
While specific check sizes are not disclosed, Kizoo Technology Capital is known for making substantial investments in its portfolio companies, particularly in the seed and early-stage financing rounds, with follow-on capabilities for promising startups.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.